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Background: Successful asthma management involves guideline-based treatment and regular
follow-up. We aimed to study the level of disease control in asthmatic individuals managed
by their GP and a dedicated nurse when using a systematic asthma consultation guide based
on Global Initiative of Asthma guidelines (GINA guidelines).
Methods: Patients aged 18e79 years with doctor-diagnosed asthma were included. When
managing the patients, the clinics were instructed to follow a consultation guide based on the
principles of the GINA guidelines. This included evaluation of symptoms, treatment, compliance,
lung function, and a scheduled follow-up appointment based on the level of asthma control:
Results: At the initial visit (baseline), 684 patients (36.8%) were classified as well-controlled, 740
(39.8%) as partly controlled and 434 (23.4%) as uncontrolled. 1784 patients had been offered
a follow-up visit and 623 (35%) had attended. A response analysis was performed, and those
participating were older (46 versus 45 years, p < 0.01), whereas other variables were similar.
A higher level of asthma control was found at the follow-up visit compared to the baseline visit
(uncontrolled asthma 29.7% and 16.5%, respectively, p < 0.001). At the time of the follow-up
visit, changes in treatment strategies were found (p< 0.01), and furthermore, level of lung func-
tion improved at the follow-up visit.
Conclusion: Although most asthmatic individuals received asthma treatment, a substantial
number still were partly or poorly controlled. The overall asthma control improved significantly
when a systematic asthma management approach was introduced and applied by dedicated
health care staff.
ª 2012 Elsevier Ltd. All rights reserved.31 3569; fax: þ45 3531 2179.
k (V. Backer).
2 Elsevier Ltd. All rights reserved.
636 V. Backer et al.Introduction
established asthma diagnosis, the patients were managedAsthma is increasing among adolescents and young adults in
western societies.1 The frequency of asthma among the
general population varies between 7% in low-prevalence
countries2 and 15e18% in other western societies.1 Further-
more, an even higher variation has been found in the prev-
alence of respiratory symptoms suggestive of asthma.1
Several studies have shown that patients’ perceptions of
their overall asthma control do not match their reported
symptomand it has beendocumented that both unawareness
and under-treatment of asthma are frequent,3e5 leading to
potential impairment in health and functional status.
Current or passive smoking and occupational factors
introduced into the asthmatic adult’s environment may
affect general health and the level of asthma control6e8;
accordingly, asthma symptoms are often overlooked or
neglected and accepted. Few surveys have shown that
asthma might be poorly controlled even in well-organized
general practices,9 this might results from symptom
neglect or possibly the lack of tradition in the primary
sector of follow-up among patients with chronic illnesses.
Many countries have attempted to address this failing,10
and have worked with different versions of a “chronic
care model (CCM)”. The CCM focus on achieving a proactive
attitude, well-trained health care professionals with
advanced knowledge of chronic diseases, and furthermore
well-educated patients able to take care of themselves
with the use of treatment schedules and action plans.11e13
The aim of this study was to investigate the current
asthma control of asthmatics in a general practice and
whether asthmatics were able to achieve better asthma
control by optimizing the management of asthma by using
simple tools and routines.Material and methods
All consecutive patients with doctor-diagnosed asthma
visiting their general practitioner (GP) were invited to
participate in the study. Patients were included when they
contacted the clinic, either in person or by telephone/
e-mail, or identified via their electronic patient record.
Identification was followed by a postal invitation.
Inclusion criteria were current doctor-diagnosed
asthma, followed in GP stetting, age 18e79 years of age
and giving informed consent. All patients with diagnosed
COPD were excluded.
The study was approved by The National Data Protection
Agency in Denmark and the Central Research Unit of
General Practice (“Multipraksisudvalget” at DSAM). The
study was submitted to the local ethics committee of Aar-
hus, Denmark (Jnr H-D-2008-FSP); the committee respon-
ded ethical approved was not needed for this type of study.
Data management was an independent national organiza-
tion (Uni-C).
Staff education
Each clinic was required to have at least one dedicated
asthma nurse who could undertake most of the asthmafollow-up visits and evaluate disease control. Following
by the asthma nurse.
Before the study was initiated, the staffs were educated
in guideline-based asthma classification and treatment.
They were requested to follow the written consultation
guide at baseline and follow-up visit. This guide instructed
the nurse in systematic handling of the patients, when
interviewing about symptoms, medication used, physical
activity and exacerbations in order to categorize current
asthma activity into controlled, partly controlled and
uncontrolled.14 Furthermore, both the GP and nurses were
educated in lung function testing. Spirometry was per-
formed using various electronic spirometers in accordance
with the ERS recommendations, and the percentage of
predicted normal values of FEV1 (FEV1% pred)
15 was
documented.
Asthma classification
Controlled asthma was defined as symptoms and use of
beta2-agonists  twice a week, no nighttime symptoms, no
limitations of physical activity, and normal lung function
(i.e. FEV1 > 80% predicted); partly controlled asthma was
defined as either symptoms and use of beta2-agonists >
twice a week, some nighttime symptoms, and some limi-
tations of physical activity, or FEV1 < 80% predicted;
uncontrolled asthma was defined as three or more positive
symptoms of all these categories. If considered necessary
by the clinic, medical treatment was initiated or optimized
in accordance with GINA guidelines. All asthma medications
were allowed and were registered by their generic name.
Follow-up visit
Follow-up visit were planned as follows: Patients with
controlled asthma were intended to be seen in the clinic
within 12 months; partly controlled asthma within 3e6
months, and uncontrolled asthma within 1e3 months.
Statistical analysis
Evaluation was performed on 1) data from the entire
baseline population. Data were collected between May 1,
2008 and November 1, 2010 and 2) data from patients who
attended a follow-up visit) with focus at the follow up visit
on improved awareness, asthma control and treatment.
Lastly, the population was divided into two groups: 1) less
than 45 years (young adults) versus older adults (46e79
years), and 2) smokers versus non-smokers (never smokers),
to investigate whether some of the older patients and some
of the smokers were non-asthmatic.
Due to a low response rate in this clinical study per-
formed in general praxis, a response analysis was per-
formed due to topics of significant importance. The analysis
of variance for continuous variables (age and FEV1) and chi-
2 test for categorical variables (sex, smoking, GINA).
After the database lock, the various drugs were classi-
fied as: all short-acting beta2-agonists as SABA; all long-
acting beta2-agonists as LABA; leukotrien-antagonists as
LTRA; all inhaled steroid as ICS; ipratropium as short-acting
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acting muscarine antagonist as LAMA; any fixed combina-
tion or combination of ICS and LABA were classified as FC-
ICS/LABA, and finally oral steroid or injection with steroid
as systemic steroid. All other asthma drugs were classified
as “others”. Following the this classifications, the anti-
asthma medication were grouped as follows: 0) others, 1)
No treatment, 2) SABA alone, or 3) LABA  SABA, 4)
LTRA  ICS, 5) ICS alone  SABA, 6) FC-ICS/LABA inde-
pendent of other treatment, 7) LAMA, 8) other and 9)
missing.
The data were analyzed with the statistical pack SPSS
version 19.0 (Chicago, Illinois). Mean and standard devia-
tions (SD) were calculated for the normally distributed
data, whereas median and interquartile ranges were used
to describe the skewed distributed data. For the continuous
variables, data were analyzed by ANOVA, followed by the
two-sample t-test to compare the groups or paired t-test to
compare changes within the group. The chi-squared test for
unpaired data was used. Values of P < 0.05 were considered
significant.Results
Population
Baseline population (only baseline visit): 2035 individuals
were enrolled during the inclusion period (Fig. 1), of whom
62.7% were women with a median age of 45.0 years (range
18e79 years). Of the 2035 individuals, 1033 were younger
than 45 years (median 33.0 years) and 1002 were older than
45 years (median 59.0 years) (Table 1).
Follow up population (baseline visit þ follow-up visit):
At the time of data analysis, 1784 patients had been in the
study so long that they had the possibility to comply with
the recommended follow up interval. Of the 1784 patients,
623(38%) patients attended a follow up visit”. Of these 623
patients, 63.4% were women; the median age was 47.0
years (18e79 years) (Table 1).
Response analysis
Of 2035, 251 (12%) had their visit 1 (baseline) so close that
they have had no time for visit 2 (follow-up), whereas 1784
had had the possibility of such a visit. Of those 1784, six
(0.3%) patients had no appointment scheduled, 623 patient
showed up, whereas 1155 (57%) patients who should haveFigure 1 Patient flow-chart of the entire baseline populationhad a follow-up visit at the time of analysis never showed
up. Leaving a calculated response rate of 35%.
The 623 patients who showed up at the second visit was
older (47.9 years) compared with those 251 who partici-
pated at the baseline visits only (45.6 years) and those 1155
patients who should have had their second visit (44.8 years)
(p < 0.01). Furthermore, those 251 newly enrolled with one
visit only had a higher lung function (92% pred), whereas
those 623 participating and those 1155 who should have
participated had similar level of lung function (86% versus
87% pred). Lastly, no differences were found in sex,
smoking status, change in smoking status and asthma
severity classified by GINA between any of the groups. In
conclusion, those who participated (had two visits) were
compared with those who dropped-out in average two years
older, but had same level of lung function, same sex,
smoking status and severity of asthma.
Baseline population
In the entire group of 2035 patients 36.8% were classified
as having well-controlled asthma, 39.8% had partly
controlled asthma, and 23.4% had uncontrolled asthma
according to the international guidelines (Table 1). In
total, 30 percent of the patients had experienced an
exacerbation within the last 12 months. Of the baseline
group, 79% had been treated with inhaled steroid before
inclusion (Table 1), and 11.5% were treated with Short-
acting beta2-agonist (SABA) and 1.5% had been
prescribed LABA only without steroid. The use of SABA only
was found to the same extent in those with normal,
moderately reduced and severely reduced FEV1 (SABA:
13.5%, 11.3% and 11.4%, respectively and LABA: 4.5%, 1.7%
and 1.2%, resepctively). In the group of patients who
received inhaled steroid, the disease was well-controlled
or partly controlled in 42.0% and 35.9%, respectively,
with significant differences compared with those without
ICS treatment of 34.4% and 41.7% (p < 0.01).
Compared with patients  45 years, younger patients
were more frequently never smokers (Table 1), p < 0.001),
had a better level of lung function >80% pred (,
(p < 0.001)), more well-controlled asthma (, (p Z 0.001)
and used more ICS alone (33.1 versus 29.5%, p < 0.05) and
less ICS in fixed combination (42.5% and 52.5%, respec-
tively, (p < 0.001).
There was a difference in distribution of smoking habits
regarding smokers, ex-smokers and never smokers,
between the younger and the older participants withas well as the population who were seen twice in the clinic.
Table 1 Characteristics of the baseline population (patients with a baseline visit) and the follow-up visit include patients with
a baseline and a follow up visit.
Baseline visit Baseline
younger <45 years
Baseline older Baseline Follow-up
population
Participants (number) 2035 1033 1002 623
Age (years) 45.0 (18e79) 33.0 (18e45) 59.0 (46e79) 47.0 (18e79)
Female (%) 62.7 61.7 63.6 63.4
Never-smokers (%) 49.7 57.3 41.4 50.4
Former smokers (%) 31.1 20.9 42.2 32.7
Current smokers (%) 19.2 21.7 16.4 16.9
FEV1%pred
<60% (%) 4.7 1.8 7.8 4.6
60e80% (%) 24.7 18.4 31.2 28.7
>80% (%) 70.7 79.8 61.1 66.7
Level of asthma control
Well-controlled (%) 36.8 41.8 31.6 26.3
Partly controlled (%) 39.8 37.3 42.4 44.2
Uncontrolled (%) 23.4 20.9 25.9 29.6
Medication
No treatment (%) 5.6 6.6 4.9a 5.4
SABA or LABA (%) 13.0 16.6 9.0 13.0
LTRA (ICS) (%) 0.5 0.7 0.5 1.0
ICS (%) 31.4 33.1 29.5a 33.1
FC-ICS (%) 47.6 42.8 52.5a 46.1
LAMA (%) 1.8 0.2 3.5b 1.4
Other (%) 0.1 0.0 0.1 0.0
SABA is short-acting beta2-agonist, LABA is long-acting beta2-agonist, LAMA is long-acting muscarine receptor antagonist, LTRA is
leukotrien antagonist, FC is defined as Fixed combination of ICS/LABA.
a p < 0.05 (young versus older).
b p < 0.001 (young versus older).
638 V. Backer et al.asthma (21.7%, 20.9%, 57.3% versus 16.4%, 42.2%, 41.4%,
p < 0.001). Tobacco consumption was found to be signifi-
cantly associated with level of lung function; as those
currently smoking had lower lung function (FEV1 < 60%
pred) compared with former and never smokers (8.6%, 5.6%
and 2.9%, respectively (p < 0.001)). Furthermore, tobacco
consumption also influenced the level of asthma control as
well-controlled asthma was less frequent among smokers
than among former or never smokers (27.1%, 34.7% and
42.7%, respectively), whereas uncontrolled asthma was
more frequent in smokers than in the two other groups
(31.8%, 24.3% and 17.6% respectively, p < 0.001). These
differences were independent of age (Table 2).Table 2 Level of asthma control in smokers and never smokers
Baseline population
smokers
Baseline popul
never smokers
Well-controlled (%) 32.1 42.7a
Partly controlled (%) 41.4 39.7
Uncontrolled (%) 26.5 17.6
a p < 0.001.
b p Z 0.059.In the group of 2035 individuals, LAMA was used by 37
(1.8%) patients (Table 1); 83% were either current or former
smokers, 89 (4.7%) patients had signs of severe airway
obstruction with a FEV1 < 60%. In this group of patient with
airway obstruction, 46 patients had uncontrolled asthma,
16 were using LAMA, 4 were using LABA only, and 10 had
a fixed combination of inhaled ICS and LABA, either alone or
in combination with LAMA.
In the group of participants above the age of 45 years
some misclassification of COPD as asthma patients might
have happened, 39% had signs of chronic airway obstruction
(Table 1), 25.9% were uncontrolled, and 3.5% used LAMA as
a single drug.in baseline and follow-up population at baselines (nZ 2035).
ation Baseline Follow-up
population smokers
Baseline Follow-up
population never smokers
24.4 29.3b
42.4 47.0
33.2 23.7
Figure 3 Change in level of control seen in the individual
changes, this figure include 525 patients who had their level of
severity and change over time noted.
Scheduled asthma management in general practice 639Follow-up visit
Patients only attending the baseline visit were younger
(44.8 yrs versus 47.9 yrs), were less uncontrolled than those
also attending the second appointment (23.5% versus
29.6%, p < 0.005) but had same level of FEV1 at first visit
(FEV1% pred >80%: 68.2% versus 63.3%). No differences
between the 2 populations were found regarding sex,
smoking status and severity based on the GINA classifica-
tions. The mean (SE) interval between the first and second
visit was 170,11 1026 and 816 days, respectively, in the three
different groups of asthma control.
The level of lung function changed during follow-up, and
fewer participants were found with signs of severe persis-
tent airflow obstruction at the follow up visit compared
with those at baseline visit (FEV1 < 70%: 18.1% versus
13.7%, respectively, p < 0.001).
A higher level of asthma control was found at the follow
up visit compare with baseline visit (Fig. 2) as many as
29.6% were uncontrolled at the time of enrollment
compared to 16.4% at the second visit (p < 0.001). Of those
well-controlled at the first visit, 73.8% remained well-
controlled at the second; of those uncontrolled at the
baseline visit, 11% remained uncontrolled with 20% partly
controlled independent of the program applied, whereas
20% remained well-controlled and 27% became well-
controlled. (Fig. 3).
Treatment differed between the younger and the older
asthmatic: at the time of inclusion the younger group used
more beta2-agonist (Table 1), used LAMA less frequently
(0.2% versus 3.5%, respectively, p < 0.001)) and, overall,
used less inhaled steroid either alone or in combination
with LABA (76% versus 81%, p < 0.001).
At the time of follow-up this pattern of treatment had
changed, a reduction in use of SABA only were found (13%
versus 5.5%, p < 0.01), and an increase in use of inhaled
steroid (33% versus 36%, p < 0.05) as well as FC-ICS/LABA
(46%e53%, p < 0.01); 89% had changed to ICS at the
follow-up visit (p < 0.001).
Possible misclassification of COPD patients at baseline
and follow-up as asthma patients has been analyzed, andFigure 2 Level of control in the follow-up group (Follow).among the young asthma patients use of either LABA (1.1%)
or LAMA (0.2%) only compared with the group of elderly
asthma patients (1.7% and 3.5%, respectively) was different
(p < 0.01), as well as the use of fixed combination FC-ICS/
LABA was 42.8 versus 52.5% (p < 0.05). Furthermore, among
smokers, elderly with asthma symptoms had more
frequently low lung function (FEV1 <60%) than younger
asthma patients (1% versus 0.2%). Furthermore, the
differences between moderate reduced level of lung
function in young and elderly patient with asthma who
were either current or former smokers was 7% versus 20%.
When combining smoking, age, level of lung function and
use of medication traditionally used in COPD, a misclassifi-
cation of 10e13% might have happened in the present
paper.Discussion
In a general practice setting, use of a standardized
program, such as the consultation guide used in this study
for follow-up visits, a dedicated asthma nurse to undertake
rating of asthma control use of asthma medication, and
measurement of lung function increased the level of well-
controlled asthma from 26% to 46% in unselected patients
visiting their GP. The frequency of uncontrolled asthma was
reduced from 30% to 16%. These positive changes in asthma
management were independent of the treatment
prescribed at the time of enrollment and independent of
age. Those patients with a history of smoking, either
current or earlier, showed a lower frequency of well-
controlled disease at study termination than never
smokers (24 versus 29%).
The diagnosis of asthma in general practice is seldom
based on objective measurements such as diagnostic
spirometry with reversibility test, day-to-day variation in
peak-flow or bronchial challenge tests. It could therefore
be argued that a part of population not least the oldest
participants or those who smoked could have had COPD. In
general, COPD most commonly develops among patients
above the age of 45 years, seldom in younger people. For
the patients  45 years in this study, 61.1% showed no signs
of irreversible airway obstruction (FEV1> 80% pred), 31.2%
had mild airway obstruction and could have had mild COPD
640 V. Backer et al.alternatively an irreversible airflow limitation to under-
treated asthma with respect to ICS and only 8.8% of the
older participants with doctor-diagnosed asthma showed
signs of possible moderate COPD according to GOLD clas-
sification rather than asthma, or a combination of asthma
and COPD.16 Furthermore, when analyzing smokers only,
airway obstruction was found to be frequent, atleast in the
elderly. These findings differed from those among partici-
pants younger than 45 years. Only 1.8% of the younger
participants had moderate obstruction and 18.4% had mild
obstruction, However, according to the treatment guide-
lines for COPD,16 LABA or LAMA should frequently be
prescribed; nevertheless, as few as 2% were using LABA
alone and as few as 3.5% were using only LAMA, indicating
that if those with signs of severe airway obstruction might
have had COPD, and not asthma. However, if the entire
group of patients with airway obstruction had COPD and
not asthma, more than 80% were treated outside the GOLD
guidelines. Finally, current tobacco use was found to be
the same among the younger and the older asthmatic
individuals, overall indicating a possible misclassification in
the group of older asthmatic individuals. On the other
hand, in GP setting among patient with asthma who is
smokers as well, some might have both asthma and COPD
and this study probably is more likely to set the scene in
the general population of asthma patients, which is
different form the selected few included in Phase II to IV
studies.
In earlier studies under-treatment of asthma has
frequently been found,5,16,17 as found in the present study.
Under-treatment is frequently associated with low aware-
ness of asthma, both among patients and healthcare
providers. The first step in achieving well-controlled
asthma in general praxis is a systematic questioning of
patients with a disease, such as asthma symptoms. Indi-
viduals at risk might be those reporting shortness of breath
during exercise, those with rhinitis, and those with cough-
ing during the daytime and nighttime. Coughing is a factor
that could interfere with the classification of asthma
severity, leading either to a milder classification, because
smokers tend to cough without regarding it as important or
to a more severe classification because cough in smokers is
probably something different form coughing due to asth-
matic inflammation. Therefore, those with asthma who
smoke might be difficult to detect or classify correctly. This
is a problem in general practice as this setting includes both
asthmatic smokers and non-smokers, which differs from
most scientific studies in general. The next step in
achieving an increased frequency of well-controlled asthma
is awareness and understanding of the pathology behind the
disease, especially among general practitioners who have
an exceptional possibility to overestimate the level of
control. Few of the current participants were likely to have
been unaware of their asthma or unaware of the treatment
possibilities as only about 10% were untreated, which is in
contrast to earlier studies.3,4,16,17 Although both patients
with asthma and their GPs were aware of their disease, the
level of treatment was too low. The young asthmatic indi-
viduals, in particular, were frequently treated with SABA
alone, despite having symptoms suggestive of mild persis-
tent asthma or worse. The present study showed that
change in treatment pattern is possible in general praxis,which is in contrast with earlier findings where well-
controlled asthma was more often found in a specialist
rather than a general practice setting.18 Our findings indi-
cate that if a GP setting is to change routines regarding
diagnosis of asthma and classification of asthma control,
access to administrative tools, such as asthma consultation
guides, and a dedicated asthma nurse are required. With
these prerequisites, both the treatment schedule and the
level of control become substantially more satisfactory. It is
important to highlight the fact that well-educated staff
increase the level of well-treated patients.19
A weakness of the present study was that the data
covered only the prescribed asthma medications and not
the asthma medication taken. Nevertheless, the main focus
was on asthma and well-treated disease, and the increase
found in asthma control was brought about either by
increased adherence or by selection of the right treatment.
Furthermore, another limitation is the large drop-out in GP
setting studies, which on the other hand is showing the day-
to-day asthma management. Those who participated most
willingly were slightly older, but level of severity of asthma
and lung function were similar. Lastly, including asthma in
eldery might also include patients with COPD. On the other
hand, among the young asthma patients use of either LABA
(1.1%) or LAMA (0.2%) only was just slightly higher in the
group of elderly asthma patients (1.7% and 3.5%,
respectively).
In conclusion, although most patients with asthma had
some kind of pharmacological asthma treatment,
a substantial number were only partly or poorly controlled
and a significant proportion experienced an exacerbation
during the previous year. This indicates extensive under-
treatment of asthma, which could be due to adherence as
the level of treatment were satisfactory. At the time of
follow-up the asthma control had improved significantly
stressing the importance of using a simple but systematic
approach when working with asthmatics.
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